江中药业股份有限公司 股权激励限制性股票回购注销实施公告

Core Points - The company announced the repurchase and cancellation of restricted stocks due to five incentive targets no longer meeting the criteria of the 2021 stock incentive plan [1][2] - A total of 149,602 restricted stocks will be repurchased and canceled, leaving 1,715,544 restricted stocks remaining under the incentive plan [2][3] - The repurchase is expected to be completed by May 23, 2025, with necessary legal and registration procedures to follow [3][4] Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks are based on the non-compliance of five incentive targets due to reasons such as job transfer, retirement, and resignation [2][4] Repurchase Details - The decision for the repurchase was approved in the board meetings held on March 18, 2025, and the legal opinion was obtained [1][4] - The company has opened a special securities account for the repurchase with the China Securities Depository and Clearing Corporation [3] Company Commitments - The board assures that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of incentive targets or creditors [4][5] - The company commits to handling any legal responsibilities arising from disputes related to the repurchase [4]